Alvespimycin (Synonyms: 17-DMAG; KOS-1022; NSC 707545)

Name: Alvespimycin
Brand: MedChemExpress
SKU: HY-10389
Rating: 5.0 (16 reviews)

Cat. No.: HY-10389 Purity: 99.59%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC₅₀ of 62 ± 29 nM.

For research use only. We do not sell to patients.

Alvespimycin Chemical Structure

CAS No. : 467214-20-6

Size	Price	Stock	Quantity
1 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 175	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Other Forms of Alvespimycin:

Alvespimycin hydrochloride In-stock

14 Publications Citing Use of MCE Alvespimycin

: Alvespimycin purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 9;10(18):8415-8429. [Abstract]; Western blot analysis of three proteins of interest in astrocytes treated with the Alvespimycin (17DMAG) for 24 h. Alvespimycin treatment increases EAAT2 and Hsp70 levels in a dose-dependent manner.

: Alvespimycin purchased from MedChemExpress. Usage Cited in: Friedrich-Alexander University Erlangen-Nuremberg. 2016 Sep 14.; pJAK2 and JAK2 expression upon TGFβ stimulation and JAK inhibitors incubation. pJAK2 and JAK2 expression in healthy human fibroblasts after stimulation with TGFβ for 3 days and incubation with TG101209, 17-DMAG or Ruxolitinib.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSP Isoform Specific Products:

View All Isoforms

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC₅₀ of 62 ± 29 nM.

IC₅₀ & Target^[1]

HSP90

62 nM (EC₅₀)

GRP94

65 nM (EC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A2058	IC₅₀	2.1 nM Compound: 17-DMAG	Cytotoxicity against human A2058 cells by MTT assay Cytotoxicity against human A2058 cells by MTT assay	[PMID: 18929486]
A549	IC₅₀	68 nM Compound: 1e, 17-DMAG	Cytotoxicity against human A549 cells after 72 hrs by celltiter-glo assay Cytotoxicity against human A549 cells after 72 hrs by celltiter-glo assay	[PMID: 19405528]
AGS	IC₅₀	0.0036 μM Compound: page 2621, table 2 footnote	Inhibition of hypoxia-induced HIF1 activation in human AGS cells by reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human AGS cells by reporter gene assay	[PMID: 18359631]
AGS	IC₅₀	0.036 μM Compound: 17-DMAG	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
AGS	IC₅₀	16 μM Compound: 17-DMAG	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	16 μM Compound: page 2621, table 2 footnote	Cytotoxicity against human AGS cells by MTT assay Cytotoxicity against human AGS cells by MTT assay	[PMID: 18359631]
BT-549	IC₅₀	17.1 μM Compound: 47; 17-DMAG	Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 33650861]
CCRF-CEM	IC₅₀	2500 nM Compound: 1e, 17-DMAG	Cytotoxicity against human paclitaxel-resistant CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay Cytotoxicity against human paclitaxel-resistant CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay	[PMID: 19405528]
CCRF-CEM	IC₅₀	540 nM Compound: 1e, 17-DMAG	Cytotoxicity against human CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by celltiter-96 aqueous one solution assay	[PMID: 19405528]
HCT-116	IC₅₀	0.05 μM Compound: 36, 17-DMAG	Cytotoxicity against human HCT116 cells by Alamar blue assay Cytotoxicity against human HCT116 cells by Alamar blue assay	[PMID: 20662534]
HCT-116	IC₅₀	0.78 μM Compound: 17-DMAG	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24582477]
HCT-116	IC₅₀	1.21 μM Compound: 17-DMAG	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24763261]
HCT-116	IC₅₀	57 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against human HCT116 cells after 72 hrs Cytotoxicity against human HCT116 cells after 72 hrs	[PMID: 19231864]
HeLa	IC₅₀	2.06 μM Compound: page 2621, table 2 footnote	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18359631]
Hep 3B2	IC₅₀	> 30 μM Compound: 17-DMAG	Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay	[PMID: 19072214]
Hep 3B2	IC₅₀	> 50 μM Compound: 17-DMAG	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	0.057 μM Compound: 17-DMAG	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis	[PMID: 20469887]
Hep 3B2	IC₅₀	0.061 μM Compound: 17-DMAG	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
Hep 3B2	IC₅₀	0.079 μM Compound: 17-DMAG	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA	[PMID: 20469887]
Hep 3B2	IC₅₀	57.2 nM Compound: 17-DMAG	Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis	[PMID: 19072214]
Hep 3B2	IC₅₀	79.5 nM Compound: 17-DMAG	Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA	[PMID: 19072214]
Hs-578T	IC₅₀	8.4 nM Compound: 47; 17-DMAG	Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 33650861]
Huh-7	EC₅₀	1.2 nM Compound: 17-DMAG	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	3.1 nM Compound: 17-DMAG	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis	[PMID: 18936191]
MCF7	IC₅₀	0.39 μM Compound: 17-DMAG	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24582477]
MCF7	IC₅₀	0.8 μM Compound: 17-DMAG	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24763261]
MCF7	IC₅₀	230 nM Compound: 1e, 17-DMAG	Cytotoxicity against human MCF7 cells after 72 hrs by celltiter-glo assay Cytotoxicity against human MCF7 cells after 72 hrs by celltiter-glo assay	[PMID: 19405528]
MCF7	IC₅₀	71 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 19231864]
MCF7	IC₅₀	862 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol	[PMID: 19231864]
MDA-MB-231	IC₅₀	45.7 μM Compound: 47; 17-DMAG	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	5.8 nM Compound: 17-DMAG	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 18929486]
MDA-MB-468	IC₅₀	1600 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs	[PMID: 19231864]
NCI-H1299	IC₅₀	0.1 μM Compound: 1c, DMAG	Inhibition of human HSP90 in human NCI-H1299 cells assessed as Akt degradation after 24 hrs by luminex assay Inhibition of human HSP90 in human NCI-H1299 cells assessed as Akt degradation after 24 hrs by luminex assay	[PMID: 21438541]
NCI-H596	IC₅₀	1100 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs	[PMID: 19231864]
PC-9	IC₅₀	0.01 μM Compound: 3; 17-DMAG	Cytotoxicity against HGF-induced erlotinib-resistant human PC9 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against HGF-induced erlotinib-resistant human PC9 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 26844689]
SK-BR-3	IC₅₀	1.34 μM Compound: 17-DMAG	Antiproliferative activity against human SKBR3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human SKBR3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24582477]
SK-BR-3	IC₅₀	230 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol	[PMID: 19231864]
SK-BR-3	IC₅₀	24 nM Compound: 1e, 17-DMAG	Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay	[PMID: 19405528]
SK-BR-3	IC₅₀	3.11 μM Compound: 17-DMAG	Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay	[PMID: 24763261]
SK-BR-3	IC₅₀	58 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against human SKBR3 cells after 72 hrs Cytotoxicity against human SKBR3 cells after 72 hrs	[PMID: 19231864]
SK-OV-3	IC₅₀	122 nM Compound: alvespimycin, 17-DMAG	Cytotoxicity against human SKOV3 cells after 72 hrs Cytotoxicity against human SKOV3 cells after 72 hrs	[PMID: 19231864]
SK-OV-3	IC₅₀	220 nM Compound: 1e, 17-DMAG	Cytotoxicity against human SKOV3 cells after 72 hrs by celltiter-glo assay Cytotoxicity against human SKOV3 cells after 72 hrs by celltiter-glo assay	[PMID: 19405528]

In Vitro

Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC₅₀ of 62 nM. Alvespimycin (17-DMAG) inhibits the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and causes down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition, for Her2 degradation with EC₅₀ of 8 ± 4 nM and 46 ± 24 nM in SKBR3 and SKOV3 cells, respectively; for Hsp70 induction with EC₅₀ of 4 ± 2 nM and 14 ± 7 nM in SKBR3 and SKOV3 cells, respectively^[1]. Compared with the vehicle control, Alvespimycin (17-DMAG) dose-dependent apoptosis (P<0.001 averaged across 24- and 48-hour time points) at concentrations of 50 nM to 500 nM, which represent pharmacologically attainable doses. Similar to many other agents, Alvespimycin (17-DMAG) also demonstrates time-dependent apoptosis (P <0.001, averaged across all doses) in chronic lymphocytic leukemia (CLL) cells with extended exposure from 24 to 48 hours. In addition,Alvespimycin (17-DMAG) is much more potent after 24 and 48 hours of treatment than 17-AAG^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The tumors are grown for two months before the start of i.p. injections every four days over one month with 0, 50, 100 and 200 mg/kg dipalmitoyl-radicicol or 0, 5, 10 and 20 mg/kg Alvespimycin (17-DMAG). Despite sample heterogeneity, the HSP90 inhibitor-treated animals have significantly lower tumour volumes than the vehicle control-treated animals. HSP90 inhibitors have been shown to cause liver toxicity in an animal model of gastrointestinal cancer. Nevertheless, the reduction in tumor size using dipalmitoyl-radicicol is statistically significant at 100 mg/kg, while Alvespimycin (17-DMAG) at either 10 or 20 mg/kg elicits a significant reduction in tumor size^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

616.75

Formula

C₃₂H₄₈N₄O₈

CAS No.

467214-20-6

Appearance

Solid

Color

Pale purple to purple

SMILES

C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (162.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6214 mL	8.1070 mL	16.2140 mL
5 mM	0.3243 mL	1.6214 mL	3.2428 mL
10 mM	0.1621 mL	0.8107 mL	1.6214 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.59%

Select Batch:

Data Sheet (281 KB) SDS (251 KB)

COA (251 KB) RP-HPLC (260 KB)

Handling Instructions (2659 KB)

References

[1]. Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49(15):4606-15. [Content Brief]

[2]. Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116(1):45-53. [Content Brief]

[3]. Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel). 2016 Aug 24;8(9). pii: E77. [Content Brief]

Cell Assay ^[2]	MTT assays are performed to determine cytotoxicity. A total of 1×10⁶ CD19-selected B cells from CLL patients are incubated for 24 or 48 hours in Alvespimycin, 17-AAG, or vehicle. MTT reagent is then added, and plates are incubated for an additional 24 hours before spectrophotometric measurement. Apoptosis is determined by staining with annexin V-fluorescein isothiocyanate and propidium iodide (PI). After exposure to drugs, cells are washed with phosphate-buffered saline and stained in 1 time binding buffer. Cell death is assessed by flow cytometry. Data are analyzed with the System II software package. A total of 10000 cells are counted for each sample. Mitochondrial membrane potential changes are assessed by staining with the lipophilic cationic dye JC-1 and analysis by flow cytometry^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] Young male CB-17/IcrHsd-Prkdc-SCID mice are used. Recombinant xenografts are made by mixing 1×10⁵ BPH1 cells and 2.5×10⁵ CAF per graft in collagen solution, allowed to gel, covered with medium and cultured overnight. Tumors are allowed to form over eight weeks, and then treated for four weeks with three different doses of dipalmitoyl-radicicol (50, 100 and 200 mg/kg) and Alvespimycin (5, 10 and 20 mg/kg) via intraperitoneal injections of compounds in sesame oil every four days. After 12 weeks in total, the mice are sacrificed, their kidneys resected, grafts cut in half and photographed before processing for histology. Graft dimensions are measured and the resultant tumour volume is calculated using the formula; volume=width × length × depth × π/6. This formula represents a conservative approach to evaluate tumour volumes, as it understates the volume of large, invasive tumours compared with smaller, non-invasive tumours. Resected grafts are fixed in 10% formalin, embedded in paraffin and processed for immunohistochemistry. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49(15):4606-15. [Content Brief] [2]. Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116(1):45-53. [Content Brief] [3]. Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel). 2016 Aug 24;8(9). pii: E77. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6214 mL	8.1070 mL	16.2140 mL	40.5351 mL
	5 mM	0.3243 mL	1.6214 mL	3.2428 mL	8.1070 mL
	10 mM	0.1621 mL	0.8107 mL	1.6214 mL	4.0535 mL
	15 mM	0.1081 mL	0.5405 mL	1.0809 mL	2.7023 mL
	20 mM	0.0811 mL	0.4054 mL	0.8107 mL	2.0268 mL
	25 mM	0.0649 mL	0.3243 mL	0.6486 mL	1.6214 mL
	30 mM	0.0540 mL	0.2702 mL	0.5405 mL	1.3512 mL
	40 mM	0.0405 mL	0.2027 mL	0.4054 mL	1.0134 mL
	50 mM	0.0324 mL	0.1621 mL	0.3243 mL	0.8107 mL
	60 mM	0.0270 mL	0.1351 mL	0.2702 mL	0.6756 mL
	80 mM	0.0203 mL	0.1013 mL	0.2027 mL	0.5067 mL
	100 mM	0.0162 mL	0.0811 mL	0.1621 mL	0.4054 mL

Alvespimycin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Alvespimycin467214-20-617-DMAG KOS-1022 NSC 707545KOS1022KOS 1022KOS-1022NSC707545NSC 707545NSC-707545HSPHeat shock proteinsInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Alvespimycin (Synonyms: 17-DMAG; KOS-1022; NSC 707545)

Customer Review

Other Forms of Alvespimycin:

Alvespimycin Related Antibodies

14 Publications Citing Use of MCE Alvespimycin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSP Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Alvespimycin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Alvespimycin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report